The gastrointestinal problems linked to NSAIDS are certainly no secret: the ability to mitigate them turned Vioxx into a blockbuster drug, that is, until it was pulled from the market because of cardiovascular problems. Now, Logical Therapeutics in-licensed rights to a pro-drug of naproxen that it thinks will have the GI-safety profile of Vioxx and the cardiovascular safety profile of naproxen.
811 Camp Horne Road
Suite 200
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
